X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216620
https://www.fiercepharma.com/pharma/abbvie-s-humira-leads-icer-s-list-unjustified-drug-price-increases-u-s
https://medicalxpress.com/news/2020-10-fostamatinib-chronic-immune-thrombocytopenia-comparisonadded.html
https://seekingalpha.com/news/3506932-novartis-strikes-expanded-use-eltrombopag-europe
http://www.pharmatimes.com/news/az_bags_two_extensions_in_latest_chmp_decisions_1292946
https://www.fiercepharma.com/marketing/dova-takes-novartis-blockbuster-2nd-doptelet-fda-nod-slashes-price?utm_source=internal&utm_medium=rss
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-29-2019-1559107900.pdf
https://www.pharmacompass.com/pdf/news/novartis-issues-voluntary-nationwide-recall-of-promacta-125-mg-for-oral-suspension-1557815611.pdf
https://www.prnewswire.com/news-releases/amgen-submits-supplemental-biologics-license-application-for-nplate-romiplostim-300769133.html
https://www.fiercepharma.com/pharma/novartis-scores-fda-nod-for-promacta-label-expansion-plus-potential-new-use-radiation
https://www.reuters.com/article/us-novartis-fda/novartis-blood-disorder-drug-gets-fda-approval-for-expanded-use-idUSKCN1NL2OY
https://endpts.com/whos-delaying-generic-competition-fda-publishes-list-of-52-branded-drugs-accused-of-gaming-the-system/
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208815
http://www.pharmatimes.com/news/data_back_first-line_use_of_novartis_eltrombopag_in_saa_1191551
http://www.pharmatimes.com/Article/16-04-08/EU_approval_for_Revolade_for_children_with_rare_blood_disorder.aspx
http://cphi-online.com/novartis-receives-eu-approval-for-revolade-as-news039928.html
http://www.pharmatimes.com/Article/15-09-02/Novartis_Revolade_wins_EU_nod_for_rare_blood_disorder.aspx
http://www.pharmatimes.com/Article/15-08-25/FDA_expands_use_of_Novartis_Promacta.aspx
http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/022291Orig1s015ltr.pdf
http://www.pharmatimes.com/Article/15-06-12/FDA_clears_Novartis_Promacta_for_paediatric_ITP_patients.aspx
http://www.fiercepharma.com/story/gsk-deals-done-now-novartis-has-deliver-cancer-growth-pledge/2015-03-02
http://www.bloomberg.com/news/articles/2015-02-04/glaxosmithkline-earnings-beat-estimates-on-hiv-cancer-drugs
http://www.gsk.com/en-gb/media/press-releases/2014/gsk-announces-us-regulatory-submission-seeking-additional-indication-for-eltrombopag-promacta/
Market Place
Share 
